On June 15, 2020, the U.S. Food & Drug Administration (FDA) revoked the Emergency Use Authorization (EUA) that permitted emergency distribution of chloroquine phosphate (CQ) and hydroxychloroquine sulfate (HCQ) from the Strategic National Stockpile. (https://www.fda.gov/media/138945/download) The FDA concluded, based on clinical trial data and the continuing failure of treatment guidelines to support use of CQ or HCQ to treat patients with COVID-19, that “it is no longer reasonable to believe that oral formulations of HCQ and CQ may be effective in treating COVID-19, nor is it reasonable to believe that the known and potential benefits of these products outweigh their known and potential risks.”
Jessica Abrahams knows the ins and outs of rules and policies that govern U.S. federal, state and local and international contracts in the government marketplace. She helps clients identify and win meaningful business opportunities, capitalize on federal appropriations and successfully navigate the various procurement processes.
View the full bio for Jessica Abrahams at the Faegre Drinker website.